Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Short term Debt (2022 - 2025)

Coeptis Therapeutics Holdings has reported Short term Debt over the past 3 years, most recently at $635489.0 for Q1 2025.

  • Quarterly results put Short term Debt at $635489.0 for Q1 2025, changed N/A from a year ago — trailing twelve months through Mar 2025 was $635489.0 (changed N/A YoY), and the annual figure for FY2024 was $1.0 million, changed.
  • Short term Debt for Q1 2025 was $635489.0 at Coeptis Therapeutics Holdings, down from $1.0 million in the prior quarter.
  • Over the last five years, Short term Debt for COEPW hit a ceiling of $1.0 million in Q4 2024 and a floor of $333335.0 in Q3 2022.
  • Median Short term Debt over the past 3 years was $635489.0 (2025), compared with a mean of $670102.7.